MINNETONKA ENTERING Rx MARKET WITH TRANSDERMAL WART REMOVAL
MINNETONKA ENTERING Rx MARKET WITH TRANSDERMAL WART REMOVAL product, the firm's corporate VP Robert Hebeisen told the New York Society of Security Analysts on Dec. 4. Trademarked Tran-sal, the product consists of salicylic acid in a transdermal patch. Minnetonka plans to launch its first prescription product in March. The firm maintains that regulatory approval from FDA is not needed to market the product. Hebeisen said that in clinical tests Tran-sal was shown to be "highly effective" in treating warts and less irritating than the leading prescription wart removers. Minnetonka said it developed the product in collaboration with the dermatology department of a mid-western university. Tran-sal will be sold in kits containing 40 transdermal pads and adhesive tape at a suggested retail price of $18.50 per kit. Minnetonka's Davron professional skin care group will market the product. The division curently markets a variety of professional soaps and skin care items through 45 independent manufacturer representatives and several hospital supply distributors. Minnetonka said the division accounts for less than 5% of corporate sales. Minnetonka had 1985 sales of approximately $124 mil.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth